# Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

> **NCT01208961** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 54 (actual)

## Conditions studied

- Severe Hypertriglyceridemia

## Interventions

- **DRUG:** Epanova (4 g) and Lovaza (4 g)
- **DRUG:** Lovaza (4 g) and Epanova (4 g)

## Key facts

- **NCT ID:** NCT01208961
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2015-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01208961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01208961, "Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01208961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*